FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283268> ?p ?o ?g. }

• W4379283268 endingPage "7001" @default.
• W4379283268 startingPage "7001" @default.
• W4379283268 abstract "7001 Background: In October 2021, brexucabtagene autoleucel (brexu-cel) became the first CAR-T cell therapy to receive FDA approval for adults (≥18 yrs) with relapsed/refractory (r/r) B-ALL. Approval was based on Phase II results of ZUMA-3, a single-arm, open-label, multicenter trial which reported on 55 treated patients with CR/CRi achieved in 71%; cytokine release syndrome (CRS) and neurologic toxicities occurred in 89% (grade 3-4, 24%) and 60% (grade 3-4, 25%), respectively. Here, we report outcomes of 76 adults with r/r B-ALL treated with post-approval brexu-cel at 13 U.S. centers. Methods: Retrospective data were collected across centers participating in a real-world outcomes collaborative of CAR-T in ALL (ROCCA). Descriptive statistics, Kaplan-Meier methodologies and cumulative incidence functions were used to summarize outcomes. Results: Among 76 patients infused, median age was 44 yrs (range, 18-81); 54% were male, 57% were non-Hispanic White (25% Hispanic), and 71% had Ph-neg disease. Median number of previous lines of therapy was 3.5 (range, 1-9) including blinatumomab in 53% and inotuzumab in 37%; 46% had relapsed post-transplant. Prior to apheresis, 69% of patients had active disease ( > 5% marrow blasts or presence of extramedullary disease), including 8 patients with CNS3 disease, 19% had detectable measurable residual disease (MRD) only, and 12% were MRD-neg. Median time from apheresis to infusion was 31 days. Lymphodepletion was predominantly with flu/cy (88%); 5 received cy/cladribine, and one patient each received single agent cy, single agent cladribine, and single agent bendamustine. Among 65 patients at least 28 days post-CAR-T with response assessed, 90.8% achieved CR/CRi, of whom 83% were MRD-neg, including CNS disease clearance in 7/8 CNS3 patients. CRS and ICANS (ASTCT criteria) occurred in 81.6% (grade 3-4, 6.6%) and 59% (grade 3-4, 38.6%), respectively. Median follow-up for survivors was 196.5 days (IQR 135.5-284.5). At last follow-up, 21 patients progressed/relapsed and 13 had died (7 of B-ALL; 6 of neurotoxicity/infection). Cumulative incidence of relapse and death in remission at 180 days were 31.5% (95% CI: 19.7%-44.1%) and 8.9% (95% CI: 3.5%-17.5%), respectively, while six-month PFS and OS were 58.8% (95% CI: 44.6%-70.5%) and 86.7% (95% CI: 75.8%-92.9%), respectively. Eleven patients underwent allogeneic transplant in CR/CRi after brexu-cel; all of whom remain in remission at last follow-up. Conclusions: These data are the first to demonstrate post-approval efficacy and toxicity rates of brexu-cel in adults with r/r B-ALL. Unlike the ZUMA-3 population, 31% of patients infused in this real-world cohort lacked morphologically detectable disease and 8 had CNS3 prior to apheresis. Our data confirm high response rates associated with brexu-cel in adult ALL, but also highlight the need for interventions to reduce associated toxicities." @default.
• W4379283268 created "2023-06-05" @default.
• W4379283268 creator A5003368910 @default.
• W4379283268 creator A5004190194 @default.
• W4379283268 creator A5007394812 @default.
• W4379283268 creator A5013695013 @default.
• W4379283268 creator A5025137989 @default.
• W4379283268 creator A5031744583 @default.
• W4379283268 creator A5034614925 @default.
• W4379283268 creator A5034654830 @default.
• W4379283268 creator A5035340502 @default.
• W4379283268 creator A5040369089 @default.
• W4379283268 creator A5045101860 @default.
• W4379283268 creator A5045161326 @default.
• W4379283268 creator A5046230996 @default.
• W4379283268 creator A5071583079 @default.
• W4379283268 creator A5071844603 @default.
• W4379283268 creator A5074975950 @default.
• W4379283268 creator A5076439561 @default.
• W4379283268 creator A5081406081 @default.
• W4379283268 creator A5086524207 @default.
• W4379283268 creator A5089779635 @default.
• W4379283268 date "2023-06-01" @default.
• W4379283268 modified "2023-10-03" @default.
• W4379283268 title "Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL." @default.
• W4379283268 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7001" @default.
• W4379283268 hasPublicationYear "2023" @default.
• W4379283268 type Work @default.
• W4379283268 citedByCount "1" @default.
• W4379283268 crossrefType "journal-article" @default.
• W4379283268 hasAuthorship W4379283268A5003368910 @default.
• W4379283268 hasAuthorship W4379283268A5004190194 @default.
• W4379283268 hasAuthorship W4379283268A5007394812 @default.
• W4379283268 hasAuthorship W4379283268A5013695013 @default.
• W4379283268 hasAuthorship W4379283268A5025137989 @default.
• W4379283268 hasAuthorship W4379283268A5031744583 @default.
• W4379283268 hasAuthorship W4379283268A5034614925 @default.
• W4379283268 hasAuthorship W4379283268A5034654830 @default.
• W4379283268 hasAuthorship W4379283268A5035340502 @default.
• W4379283268 hasAuthorship W4379283268A5040369089 @default.
• W4379283268 hasAuthorship W4379283268A5045101860 @default.
• W4379283268 hasAuthorship W4379283268A5045161326 @default.
• W4379283268 hasAuthorship W4379283268A5046230996 @default.
• W4379283268 hasAuthorship W4379283268A5071583079 @default.
• W4379283268 hasAuthorship W4379283268A5071844603 @default.
• W4379283268 hasAuthorship W4379283268A5074975950 @default.
• W4379283268 hasAuthorship W4379283268A5076439561 @default.
• W4379283268 hasAuthorship W4379283268A5081406081 @default.
• W4379283268 hasAuthorship W4379283268A5086524207 @default.
• W4379283268 hasAuthorship W4379283268A5089779635 @default.
• W4379283268 hasConcept C121332964 @default.
• W4379283268 hasConcept C126322002 @default.
• W4379283268 hasConcept C141071460 @default.
• W4379283268 hasConcept C142424586 @default.
• W4379283268 hasConcept C188313352 @default.
• W4379283268 hasConcept C2778020697 @default.
• W4379283268 hasConcept C2778461978 @default.
• W4379283268 hasConcept C2779015954 @default.
• W4379283268 hasConcept C2779134260 @default.
• W4379283268 hasConcept C2780850621 @default.
• W4379283268 hasConcept C2909962599 @default.
• W4379283268 hasConcept C2911091166 @default.
• W4379283268 hasConcept C3008058167 @default.
• W4379283268 hasConcept C524204448 @default.
• W4379283268 hasConcept C71924100 @default.
• W4379283268 hasConcept C87355193 @default.
• W4379283268 hasConceptScore W4379283268C121332964 @default.
• W4379283268 hasConceptScore W4379283268C126322002 @default.
• W4379283268 hasConceptScore W4379283268C141071460 @default.
• W4379283268 hasConceptScore W4379283268C142424586 @default.
• W4379283268 hasConceptScore W4379283268C188313352 @default.
• W4379283268 hasConceptScore W4379283268C2778020697 @default.
• W4379283268 hasConceptScore W4379283268C2778461978 @default.
• W4379283268 hasConceptScore W4379283268C2779015954 @default.
• W4379283268 hasConceptScore W4379283268C2779134260 @default.
• W4379283268 hasConceptScore W4379283268C2780850621 @default.
• W4379283268 hasConceptScore W4379283268C2909962599 @default.
• W4379283268 hasConceptScore W4379283268C2911091166 @default.
• W4379283268 hasConceptScore W4379283268C3008058167 @default.
• W4379283268 hasConceptScore W4379283268C524204448 @default.
• W4379283268 hasConceptScore W4379283268C71924100 @default.
• W4379283268 hasConceptScore W4379283268C87355193 @default.
• W4379283268 hasIssue "16_suppl" @default.
• W4379283268 hasLocation W43792832681 @default.
• W4379283268 hasOpenAccess W4379283268 @default.
• W4379283268 hasPrimaryLocation W43792832681 @default.
• W4379283268 hasRelatedWork W2003938723 @default.
• W4379283268 hasRelatedWork W2047967234 @default.
• W4379283268 hasRelatedWork W2118496982 @default.
• W4379283268 hasRelatedWork W2148022022 @default.
• W4379283268 hasRelatedWork W2351796763 @default.
• W4379283268 hasRelatedWork W2439875401 @default.
• W4379283268 hasRelatedWork W3113171896 @default.
• W4379283268 hasRelatedWork W4225253017 @default.
• W4379283268 hasRelatedWork W4379283268 @default.
• W4379283268 hasRelatedWork W2525756941 @default.
• W4379283268 hasVolume "41" @default.
• W4379283268 isParatext "false" @default.

• next